Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients
Amgen is conducting Phase 1 study to evaluate the safety and tolerability of AMG 691 in healthy participants and those with mild-to-moderate asthma.
Indication
Clinical and regulatory intelligence for Asthma with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.